| Malignant pheochromocytoma: current status and initiatives for future progress G Eisenhofer, SR Bornstein, FM Brouwers, NKV Cheung, PL Dahia, ... Endocrine-related cancer 11 (3), 423-436, 2004 | 470 | 2004 |
| Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project HJ Brisse, MB McCarville, C Granata, KB Krug, SL Wootton-Gorges, ... Radiology 261 (1), 243-257, 2011 | 452 | 2011 |
| Pheochromocytomas: Imaging with 2-[Fluorine-18]fluoro-2-deoxy-d-glucose PET1 BL Shulkin, NW Thompson, B Shapiro, IR Francis, JC Sisson Radiology 212 (1), 35-41, 1999 | 370 | 1999 |
| Criteria for evaluation of disease extent by 123I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force KK Matthay, B Shulkin, R Ladenstein, J Michon, F Giammarile, ... British journal of cancer 102 (9), 1319-1326, 2010 | 241 | 2010 |
| Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial R Mody, A Naranjo, C Van Ryn, LY Alice, WB London, BL Shulkin, ... The lancet oncology 18 (7), 946-957, 2017 | 239 | 2017 |
| Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children’s oncology group GA Yanik, MT Parisi, BL Shulkin, A Naranjo, SG Kreissman, WB London, ... Journal of nuclear medicine 54 (4), 541-548, 2013 | 210 | 2013 |
| 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma SE Sharp, BL Shulkin, MJ Gelfand, S Salisbury, WL Furman Journal of Nuclear Medicine 50 (8), 1237-1243, 2009 | 207 | 2009 |
| PET scanning with hydroxyephedrine: an approach to the localization of pheochromocytoma BL Shulkin, DM Wieland, M Schwaiger, NW Thompson, IR Francis, ... Journal of Nuclear medicine 33 (6), 1125-1131, 1992 | 202 | 1992 |
| Neuroblastoma: positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy. BL Shulkin, RJ Hutchinson, VP Castle, GA Yanik, B Shapiro, JC Sisson Radiology 199 (3), 743-750, 1996 | 187 | 1996 |
| Current concepts on the diagnostic use of MIBG in children BL Shulkin, B Shapiro Journal of Nuclear Medicine 39 (4), 679-688, 1998 | 169 | 1998 |
| Use of [18F]Fluorodeoxyglucose Positron Emission Tomography in Evaluating Locally Recurrent and Metastatic Adrenocortical Carcinoma GC Mackie, BL Shulkin, RC Ribeiro, FP Worden, PG Gauger, RJ Mody, ... The Journal of Clinical Endocrinology & Metabolism 91 (7), 2665-2671, 2006 | 151 | 2006 |
| Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14. 18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma F Navid, PM Sondel, R Barfield, BL Shulkin, RA Kaufman, JA Allay, J Gan, ... Journal of clinical oncology 32 (14), 1445, 2014 | 147 | 2014 |
| A pilot trial of humanized anti-GD2 monoclonal antibody (hu14. 18K322A) with chemotherapy and natural killer cells in children with recurrent/refractory neuroblastoma SM Federico, MB McCarville, BL Shulkin, PM Sondel, JA Hank, P Hutson, ... Clinical Cancer Research 23 (21), 6441-6449, 2017 | 144 | 2017 |
| Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial RE Ware, RC Rees, SA Sarnaik, RV Iyer, OA Alvarez, JF Casella, ... The Journal of pediatrics 156 (1), 66-70. e1, 2010 | 144 | 2010 |
| Pilot study of iodine-131–metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma GA Yanik, JE Levine, KK Matthay, JC Sisson, BL Shulkin, B Shapiro, ... Journal of Clinical Oncology 20 (8), 2142-2149, 2002 | 141 | 2002 |
| PET and PET/CT in pediatric oncology H Jadvar, LP Connolly, FH Fahey, BL Shulkin Seminars in nuclear medicine 37 (5), 316-331, 2007 | 137 | 2007 |
| Targeting metabolic reprogramming by influenza infection for therapeutic intervention HS Smallwood, S Duan, M Morfouace, S Rezinciuc, BL Shulkin, A Shelat, ... Cell reports 19 (8), 1640-1653, 2017 | 136 | 2017 |
| Pediatrics: diagnosis of neuroblastoma SE Sharp, MJ Gelfand, BL Shulkin Seminars in nuclear medicine 41 (5), 345-353, 2011 | 130 | 2011 |
| Irinotecan, temozolomide, and dinutuximab with GM-CSF in children with refractory or relapsed neuroblastoma: a report from the Children’s Oncology Group R Mody, AL Yu, A Naranjo, FF Zhang, WB London, BL Shulkin, MT Parisi, ... Journal of Clinical Oncology 38 (19), 2160-2169, 2020 | 129 | 2020 |
| Long-term follow-up of a phase III study of ch14. 18 (dinutuximab)+ cytokine immunotherapy in children with high-risk neuroblastoma: COG study ANBL0032 AL Yu, AL Gilman, MF Ozkaynak, A Naranjo, MB Diccianni, J Gan, ... Clinical Cancer Research 27 (8), 2179-2189, 2021 | 127 | 2021 |
